

Imam Waked

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112892/publications.pdf>

Version: 2024-02-01

154
papers

8,798
citations

108046

37
h-index

51423

90
g-index

155
all docs

155
docs citations

155
times ranked

11002
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature. Journal of Gastrointestinal Cancer, 2023, 54, 275-281.	0.6	2
2	Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries. Clinical Infectious Diseases, 2022, 74, 513-516.	2.9	1
3	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
4	The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi Journal of Gastroenterology, 2022, 28, 3.	0.5	12
5	Reply to: "Correspondence about "Efficacy and safety of basiliximab". Annals of Hepatology, 2022, 27, 100679.	0.6	0
6	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
7	Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab Journal of Gastroenterology, 2022, 23, 120-124.	0.4	1
8	Case study of hepatitis C virus control in Egypt: impact of access program. Antiviral Therapy, 2022, 27, 135965352110675.	0.6	6
9	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	1.1	1
10	International multicenter validation of <scp>GES</scp> score for <scp>HCC</scp> risk stratification in chronic hepatitis C patients. Journal of Viral Hepatitis, 2022, 29, 807-816.	1.0	4
11	Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Review of Anti-Infective Therapy, 2021, 19, 1053-1059.	2.0	8
12	Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. The Lancet Gastroenterology and Hepatology, 2021, 6, 57-64.	3.7	110
13	Impact of COVID-19 on global HCV elimination efforts. Journal of Hepatology, 2021, 74, 31-36.	1.8	189
14	Ravidasvir hydrochloride for genotype 1 hepatitis C treatment. Drugs of Today, 2021, 57, 199.	0.7	1
15	Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study. Global Health, Science and Practice, 2021, 9, 187-200.	0.6	35
16	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Review of Anti-Infective Therapy, 2021, , 1-8.	2.0	4
17	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 925-935.	1.8	4
18	Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. Journal of Medical Virology, 2021, 93, 6750-6759.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	3.6	92
20	Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study. <i>Annals of Hepatology</i> , 2020, 19, 541-545.	0.6	11
21	GES: A validated simple score to predict the risk of HCC in patients with HCV-associated advanced liver fibrosis after oral antivirals. <i>Liver International</i> , 2020, 40, 2828-2833.	1.9	31
22	Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1553-1558.	0.8	8
23	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020, 382, 1166-1174.	13.9	160
24	What's in a name? Renaming "NAFLD" to "MAFLD". <i>Liver International</i> , 2020, 40, 1254-1261.	1.9	212
25	Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers. <i>Clinical and Experimental Immunology</i> , 2020, 203, 3-12.	1.1	9
26	Paracentesis-induced circulatory dysfunction: are there albumin alternatives?. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	3
27	High efficacy of low-dose albumin infusion in the prevention of paracentesis-induced circulatory dysfunction. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	1
28	Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. <i>World Journal of Hepatology</i> , 2020, 12, 99-107.	0.8	15
29	HCV treatment with direct acting antivirals improves the insulin sensitivity. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 749-754.	2.0	13
30	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1009-1016.	1.4	5
31	Intermediate stage hepatocellular carcinoma: a summary review. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 105-117.	1.8	21
32	Direct-acting antiviral drugs improve the female sexual burden associated with chronic HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 919-926.	2.0	3
33	High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 907-914.	1.4	4
34	Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 16-23.	0.8	14
35	Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1604-1610.	1.4	17
36	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. <i>Clinical Liver Disease</i> , 2019, 14, 203-206.	1.0	16
38	Interleukin 28A rs12980602 and interleukin 28B rs8103142 genotypes could be protective against HCV infection among Egyptians. <i>Immunologic Research</i> , 2019, 67, 123-133.	1.3	4
39	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	3.7	370
40	Clinical Epidemiology of Hepatitis C Virus. , 2019, , 149-170.		1
41	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. <i>Gut</i> , 2019, 68, 721-728.	6.1	34
42	Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2019, 11, 542-552.	0.8	18
43	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 26-32.	0.4	9
44	Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx252.	0.4	22
45	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
46	Effectiveness of sofosbuvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2018, 68, 53-62.	1.8	17
47	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. <i>Journal of Hepatology</i> , 2018, 68, 691-698.	1.8	50
48	Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018, 68, 814-826.	1.8	35
49	Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 207-211.	0.8	26
50	Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 421-431.	1.9	86
51	Health: redefined. <i>Pan African Medical Journal</i> , 2018, 30, 292.	0.3	18
52	Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 109-119.	1.8	15
53	One step closer to elimination of hepatitis C in Egypt. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 665.	3.7	26
54	High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. <i>International Journal of Infectious Diseases</i> , 2018, 75, 109-114.	1.5	37

#	ARTICLE	IF	CITATIONS
55	Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 379-380.	1.9	1
56	High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection. <i>Journal of Medical Virology</i> , 2018, 90, 1841-1847.	2.5	7
57	Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians. <i>Archives of Virology</i> , 2018, 163, 2433-2442.	0.9	16
58	Retreatment of hepatitis C virus: can it get any better?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 523-524.	3.7	1
59	Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE study. <i>Journal of Medical Virology</i> , 2018, 90, 1739-1744.	2.5	3
60	Ravidasvir. Second-generation NS5A inhibitor, Treatment of hepatitis C virus infection. <i>Drugs of the Future</i> , 2018, 43, 0097.	0.0	0
61	Hepatitis C in Egypt – past, present, and future. <i>International Journal of General Medicine</i> , 2017, Volume 10, 1-6.	0.8	130
62	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
63	National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. <i>Journal of Viral Hepatitis</i> , 2017, 24, 262-267.	1.0	145
64	Sofosbuvir-based treatment regimens: real life results of 14 409 chronic <sc>HCV</sc> genotype 4 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 681-687.	1.9	65
65	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	2.9	66
66	microRNA-34a and natural killer cells: an immuno-epigenetic approach to halt hepatocellular carcinoma progression. <i>Journal of Hepatology</i> , 2017, 66, S231-S232.	1.8	0
67	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, 83-92.	0.4	4
68	Utility of post-liver transplantation MELD and delta MELD in predicting early and late mortality. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1424-1427.	0.8	7
69	Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV. <i>Journal of Hepatology</i> , 2017, 66, S703-S704.	1.8	1
70	Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4). <i>Journal of Hepatology</i> , 2017, 66, S705.	1.8	0
71	PALBI - the platelet-albumin-bilirubin score " a better predictor of outcome of acute variceal bleeding. <i>Journal of Hepatology</i> , 2017, 66, S564.	1.8	1
72	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. <i>Growth Factors</i> , 2017, 35, 76-87.	0.5	40

#	ARTICLE	IF	CITATIONS
73	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 348-353.	0.5	4
74	Economic Evaluation of New HCV Treatments in Egypt. <i>Value in Health</i> , 2017, 20, A635.	0.1	1
75	Estimating <sc>HCV</sc> disease burden volume 4 (editorial). <i>Journal of Viral Hepatitis</i> , 2017, 24, 4-7.	1.0	8
76	Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 102-110.	1.0	25
77	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic <sc>HCV</sc> genotype <sc>IV</sc> infected patients. <i>Liver International</i> , 2017, 37, 534-541.	1.9	51
78	Reply to "Comment on Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion". <i>British Journal of Cancer</i> , 2017, 117, e6-e6.	2.9	0
79	Hepatitis C treatment: where are we now?. <i>International Journal of General Medicine</i> , 2017, Volume 10, 39-52.	0.8	86
80	Hepatitis C infection in Egypt: prevalence, impact and management strategies. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 17-25.	0.9	129
81	Proteomic Patterns in Serum and Urine of Patients Infected with <i>Schistosoma mansoni</i> : Basis for New Biomarker. <i>Journal of Bacteriology & Parasitology</i> , 2016, 07, .	0.2	0
82	P-B10 Egyptian healthcare workers and Hepatitis C virus vaccines. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 76.	0.9	0
83	Khat-induced liver injuries: A report of two cases. <i>Arab Journal of Gastroenterology</i> , 2016, 17, 45-48.	0.4	7
84	MIR-155: A Double Faced Microrna with Respect to its Impact on Tumorigenesis in both Natural Killer Cells and their Target Hepatocytes. <i>Journal of Hepatology</i> , 2016, 64, S518-S519.	1.8	0
85	Efficacy and Safety of Direct Acting Antiviral Therapy for HCV Genotype 4 in Egypt; Multicenter Real Life Experience. <i>Journal of Hepatology</i> , 2016, 64, S791-S792.	1.8	0
86	Let-7a; A Single Microrna with Opposing Cell-Specific-Tumorigenic Action in both Natural Killer Cells and their Target Hepatocytes. <i>Journal of Hepatology</i> , 2016, 64, S508.	1.8	0
87	Restoring the Expression of Endogenous IGF-1 by MIR-486 in NK Cells of HCC Patients Augments its Cytolytic Activity against Hepatoma Cell Lines. <i>Journal of Hepatology</i> , 2016, 64, S522.	1.8	0
88	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	1.3	2
89	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 36-44.	3.7	61
90	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. <i>Growth Factors</i> , 2016, 34, 128-140.	0.5	49

#	ARTICLE	IF	CITATIONS
91	Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, S772.	1.8	4
92	Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults with Chronic HCV Genotype 4 Infection (Agate-II). <i>Journal of Hepatology</i> , 2016, 64, S772.	1.8	2
93	Final Results of the Pyramid 1 Study, a Phase 3 Registrational Trial of Ravidasvir (PPI-668) and Sofosbuvir in HCV Genotype-4 Patients: High Rates of Sustained Viral Clearance in Cirrhotic and Non-Cirrhotic Patients. <i>Journal of Hepatology</i> , 2016, 64, S770.	1.8	4
94	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. <i>Human Immunology</i> , 2016, 77, 667-673.	1.2	44
95	Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 2093-2097.	0.5	4
96	The Effect of Eltrombopag (Promecta) on Thrombocytopenia in Egyptian Patients with Chronic Hepatitis C. <i>Journal of Gastroenterology and Hepatology Research</i> , 2016, 5, 2088-2092.	0.2	0
97	Long-term effect of mass chemotherapy of <i>Schistosoma mansoni</i> on infection rate and diagnosis accuracy. <i>International Journal of Infectious Diseases</i> , 2015, 41, 79-82.	1.5	2
98	P0482 : Improving natural killer cells cytotoxicity and harnessing hepatocyte cancer progression by MIR-486-5P. <i>Journal of Hepatology</i> , 2015, 62, S495.	1.8	1
99	A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients. <i>Apmis</i> , 2015, 123, 482-489.	0.9	4
100	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. <i>World Journal of Gastroenterology</i> , 2015, 21, 5654.	1.4	9
101	Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 696-706.	1.9	70
102	P1351 : An open-label study to evaluate the efficacy and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection in Egypt. <i>Journal of Hepatology</i> , 2015, 62, S863-S864.	1.8	2
103	Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015, 35, 27-34.	1.9	29
104	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. <i>Medical Oncology</i> , 2015, 32, 432.	1.2	19
105	Spontaneous Regression of HCC: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e112.	2.4	0
106	P1346 : Study protocol for a partly randomised, open-label phase IIA trial of once-daily simeprevir combined with sofosbuvir for the treatment of HCV genotype 4 infected patients with or without cirrhosis (OSIRIS). <i>Journal of Hepatology</i> , 2015, 62, S861-S862.	1.8	0
107	Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. <i>Archives of Virology</i> , 2015, 160, 1741-1750.	0.9	12
108	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , 2015, 9, 251-257.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection. Archives of Virology, 2015, 160, 2833-2837.	0.9	16
110	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956.	6.1	101
111	Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 673.	0.8	77
112	Normal liver stiffness: A study in living donors with normal liver histology. World Journal of Hepatology, 2015, 7, 1149.	0.8	18
113	Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6929-6934.	0.5	4
114	Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt. PLoS ONE, 2014, 9, e90929.	1.1	61
115	Peri-Operative Lactate in Living Donor Liver Transplantation.. Transplantation, 2014, 98, 789.	0.5	0
116	Optimal Management of HCV Genotype 4. Current Hepatology Reports, 2014, 13, 286-294.	0.4	0
117	Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis, 2014, 21, 60-89.	1.0	161
118	Female Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C. Journal of Sexual Medicine, 2014, 11, 768-775.	0.3	12
119	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	1.0	372
120	Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis, 2014, 21, 5-33.	1.0	211
121	Schistosomiasis Does Not Affect the Outcome of HCV Infection in Genotype 4-Infected Patients. American Journal of Tropical Medicine and Hygiene, 2014, 90, 823-829.	0.6	7
122	P1164 THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN EGYPT: FUTURE IMPACT OF VARYING TREATMENT STRATEGIES. Journal of Hepatology, 2014, 60, S472.	1.8	1
123	P533 TRANSIENT ELASTOGRAPHY CAN PREDICT HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2014, 60, S247.	1.8	0
124	The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab Journal of Gastroenterology, 2014, 15, 45-52.	0.4	88
125	Cross Reactive Cellular Immune Response to HCV Genotype 1 and 4 Antigens among Genotype 4 Exposed Subjects. PLoS ONE, 2014, 9, e101264.	1.1	10
126	Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. Journal of Clinical Virology, 2013, 57, 24-28.	1.6	22

#	ARTICLE	IF	CITATIONS
127	Prevention of paracentesis-induced circulatory dysfunction. <i>Egyptian Liver Journal</i> , 2013, 3, 118-125.	0.3	5
128	Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 98-103.	0.7	38
129	Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. <i>Journal of Proteome Research</i> , 2011, 10, 1828-1836.	1.8	88
130	PP-088 Incidence of genotypic resistance to lamivudine long-term therapy in chronic hepatitis B genotype D. <i>International Journal of Infectious Diseases</i> , 2011, 15, S70.	1.5	0
131	PP-129 Incidence of acquiring hepatitis B and C virus infection in hemodialysis patients. <i>International Journal of Infectious Diseases</i> , 2011, 15, S81.	1.5	0
132	570 OUTFLOW RECONSTRUCTION USING NATIVE LIVER VEINS IN RIGHT LOBE GRAFTS WITHOUT MHV HARVESTING: 3 YEARS EXPERIENCE. <i>Journal of Hepatology</i> , 2011, 54, S232.	1.8	0
133	Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. <i>Hpb</i> , 2011, 13, 385-390.	0.1	25
134	Evaluation of different regimens of oral antibiotics in secondary prevention of spontaneous bacterial peritonitis in cirrhotic patients. <i>Egyptian Liver Journal</i> , 2011, 1, 69-72.	0.3	1
135	Hemodynamic effects of 3 months of therapy with midodrine in cirrhotic patients with and without ascites. <i>Egyptian Liver Journal</i> , 2011, 1, 61-68.	0.3	1
136	Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). <i>Hepatology International</i> , 2009, 3, 323-333.	1.9	88
137	Diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2009, 15, 1301.	1.4	140
138	273 MELD, CHILD SCORE, AND FIBROSIS INDICES IN PREDICTING OUTCOME OF ACUTE VARICEAL BLEEDING. <i>Journal of Hepatology</i> , 2008, 48, S110.	1.8	0
139	Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. <i>World Journal of Gastroenterology</i> , 2008, 14, 4300.	1.4	590
140	202 Predictors of early rebleeding following endoscopic control of variceal bleeding. <i>Journal of Hepatology</i> , 2006, 44, S83.	1.8	1
141	Serum Islet Cell Autoantibodies During Interferon $\hat{\pm}$ Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis. <i>Clinical and Developmental Immunology</i> , 2006, 13, 11-15.	3.3	2
142	Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma Cytokines Pattern in Patients with Combined Hepatitis C Virus and <i>Schistosoma mansoni</i> Infections. <i>Scandinavian Journal of Immunology</i> , 2005, 61, 87-91.	1.3	31
143	High Prevalence of Occult Hepatitis B in Patients with Advanced Liver Disease and Patients with Hepatitis C. <i>American Journal of Gastroenterology</i> , 2005, 100, S142.	0.2	1
144	Hepatitis B and C Viral Markers among Family Members of Patients with Advanced Liver Disease and Occult Hepatitis B. <i>American Journal of Gastroenterology</i> , 2005, 100, S144.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Band ligation versus medical therapy in prevention of variceal rebleeding: A Randomized controlled study in schistosomal hepatic fibrosis and HCV coinfection. <i>Gastroenterology</i> , 2003, 124, A663-A664.	0.6	2
146	Role of hepatitis C infection in chronic liver disease in Egypt.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 436-442.	0.6	102
147	Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patients with biliary obstruction. A randomized controlled trial. <i>American Journal of Gastroenterology</i> , 2000, 95, 2488-2488.	0.2	3
148	Duplex calculation of portal collateral flow in cirrhosis: Correlation with size of varices. <i>Gastroenterology</i> , 2000, 118, A966.	0.6	0
149	Iatrogenic Biliary Injuries: Patterns and Surgical Management. <i>Digestive Surgery</i> , 1997, 14, 534-539.	0.6	2
150	Non Hodgkin lymphoma (NHL) & hepatitis C in Egypt: Prevalence, clinical characteristics & response to therapy in a randomized controlled trial. <i>European Journal of Cancer</i> , 1997, 33, S268-S269.	1.3	0
151	Analysis of Long-Term Endoscopic Surveillance During Follow-up After Variceal Sclerotherapy From a 13-Year Experience. <i>American Journal of Medicine</i> , 1997, 102, 192-199.	0.6	21
152	Biliary Complications of Fasciola Hepatica. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 309-311.	1.1	15
153	High prevalence of hepatitis C in Egyptian patients with chronic liver disease.. <i>Gut</i> , 1995, 37, 105-107.	6.1	62
154	Experience with Interferon in Chronic Hepatitis B in Egypt. <i>Journal of Chemotherapy</i> , 1990, 2, 310-318.	0.7	19